Andra Zamurs

Pharmacological Properties of N-(3,5-Diamino-6-chloropyrazine-2-carbonyl)-N′-4-[4-(2,3-dihydroxypropoxy)phenyl]butyl-guanidine Methanesulfonate (552-02), a Novel Epithelial Sodium Channel Blocker with Potential Clinical Efficacy for Cystic Fibrosis Lung Disease

Kevin B. Johnson, M. Donowitz, J. S. St. George, 2008, Journal of Pharmacology and Experimental Therapeutics.

Evaluation of Second Generation Amiloride Analogs as Therapy for Cystic Fibrosis Lung Disease

R. Boucher, A. M. Paradiso, S. Hopkins, 2004, Journal of Pharmacology and Experimental Therapeutics.

Design, Synthesis, and Structure−Activity Relationships of Novel 2-Substituted Pyrazinoylguanidine Epithelial Sodium Channel Blockers: Drugs for Cystic Fibrosis and Chronic Bronchitis

R. Boucher, A. Usyatinsky, B. Sargent, 2006 .

Pharmacological Properties of N-(3,5-Diamino-6-chloropyrazine-2-carbonyl)-N′-4-[4-(2,3-dihydroxypropoxy)phenyl]butyl-guanidine Methanesulfonate (552-02), a Novel Epithelial Sodium Channel Blocker with Potential Clinical Efficacy for Cystic Fibrosis Lung Disease

M. Donowitz, J. S. St. George, R. Boucher, 2008, Journal of Pharmacology and Experimental Therapeutics.